NZ738844A - Nucleophilic catalysts for oxime linkage - Google Patents
Nucleophilic catalysts for oxime linkageInfo
- Publication number
- NZ738844A NZ738844A NZ738844A NZ73884413A NZ738844A NZ 738844 A NZ738844 A NZ 738844A NZ 738844 A NZ738844 A NZ 738844A NZ 73884413 A NZ73884413 A NZ 73884413A NZ 738844 A NZ738844 A NZ 738844A
- Authority
- NZ
- New Zealand
- Prior art keywords
- water soluble
- soluble polymer
- group
- active aminooxy
- aminooxy group
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Water Supply & Treatment (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261647814P | 2012-05-16 | 2012-05-16 | |
| US13/488,043 US8809501B2 (en) | 2009-07-27 | 2012-06-04 | Nucleophilic catalysts for oxime linkage |
| NZ724828A NZ724828A (en) | 2012-05-16 | 2013-05-16 | Nucleophilic catalysts for oxime linkage |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ738844A true NZ738844A (en) | 2018-12-21 |
Family
ID=48579473
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ738844A NZ738844A (en) | 2012-05-16 | 2013-05-16 | Nucleophilic catalysts for oxime linkage |
| NZ701945A NZ701945A (en) | 2012-05-16 | 2013-05-16 | Nucleophilic catalysts for oxime linkage |
| NZ724828A NZ724828A (en) | 2012-05-16 | 2013-05-16 | Nucleophilic catalysts for oxime linkage |
| NZ738846A NZ738846A (en) | 2012-05-16 | 2013-05-16 | Nucleophilic catalysts for oxime linkage |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ701945A NZ701945A (en) | 2012-05-16 | 2013-05-16 | Nucleophilic catalysts for oxime linkage |
| NZ724828A NZ724828A (en) | 2012-05-16 | 2013-05-16 | Nucleophilic catalysts for oxime linkage |
| NZ738846A NZ738846A (en) | 2012-05-16 | 2013-05-16 | Nucleophilic catalysts for oxime linkage |
Country Status (12)
| Country | Link |
|---|---|
| EP (3) | EP4019049A1 (cg-RX-API-DMAC7.html) |
| JP (5) | JP6195611B2 (cg-RX-API-DMAC7.html) |
| KR (4) | KR102287040B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN109620963B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2013204754C1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112014028636B1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2873756C (cg-RX-API-DMAC7.html) |
| EA (2) | EA035506B1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX360594B (cg-RX-API-DMAC7.html) |
| NZ (4) | NZ738844A (cg-RX-API-DMAC7.html) |
| SG (3) | SG10201911328QA (cg-RX-API-DMAC7.html) |
| WO (2) | WO2013173557A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013204754C1 (en) * | 2012-05-16 | 2018-10-11 | Takeda Pharmaceutical Company Limited | Nucleophilic Catalysts for Oxime Linkage |
| CN109963579A (zh) * | 2016-11-14 | 2019-07-02 | 诺华股份有限公司 | 用于治疗软骨损伤和关节炎的方法和组合物 |
| JP7002036B2 (ja) * | 2016-11-17 | 2022-01-20 | パナソニックIpマネジメント株式会社 | 膜電極接合体および固体酸化物形燃料電池 |
| US11786586B2 (en) | 2016-12-23 | 2023-10-17 | Aoa Dx | Carbohydrate structures and uses thereof |
| CN108503901B (zh) * | 2018-04-17 | 2020-07-07 | 哈尔滨工业大学 | 一种抗菌普鲁兰多糖/壳聚糖复合食品包装膜的制备方法 |
| US11845989B2 (en) | 2019-01-23 | 2023-12-19 | Regeneron Pharmaceuticals, Inc. | Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors |
| CA3126476A1 (en) | 2019-01-23 | 2020-07-30 | Regeneron Pharmaceuticals, Inc. | Treatment of ophthalmic conditions with angiopoietin-like 7 (angptl7) inhibitors |
| WO2022182768A1 (en) | 2021-02-26 | 2022-09-01 | Regeneron Pharmaceuticals, Inc. | Treatment of inflammation with glucocorticoids and angiopoietin-like 7 (angptl7) inhibitors |
| WO2023171638A1 (ja) | 2022-03-07 | 2023-09-14 | 株式会社カネカ | グルタチオンを含む粒状組成物の製造方法 |
| WO2025133203A1 (en) * | 2023-12-22 | 2025-06-26 | Pam Theragnostics Gmbh | Compounds and methods for a long-lasting pam |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS54113492A (en) | 1978-02-24 | 1979-09-05 | Sanyo Chem Ind Ltd | Preparation of glucoprotein derivative |
| US4356170A (en) | 1981-05-27 | 1982-10-26 | Canadian Patents & Development Ltd. | Immunogenic polysaccharide-protein conjugates |
| US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
| US5198349A (en) | 1986-01-03 | 1993-03-30 | Genetics Institute, Inc. | Method for producing factor VIII:C and analogs |
| US5250421A (en) | 1986-01-03 | 1993-10-05 | Genetics Institute, Inc. | Method for producing factor VIII:C-type proteins |
| JPH0387173A (ja) | 1987-09-10 | 1991-04-11 | Teijin Ltd | ヒト活性化天然型ファクター8cの製造方法及びそれに用いる形質転換体 |
| US5846951A (en) | 1991-06-06 | 1998-12-08 | The School Of Pharmacy, University Of London | Pharmaceutical compositions |
| ATE198277T1 (de) | 1992-10-02 | 2001-01-15 | Genetics Inst | Zusammensetzung, welche den koagulationsfaktor viii beinhaltet; verfahren zu deren herstellung und die benutzung eines oberflächenaktiven stoffes als stabilisator |
| NZ250375A (en) * | 1992-12-09 | 1995-07-26 | Ortho Pharma Corp | Peg hydrazone and peg oxime linkage forming reagents and protein derivatives |
| WO1994028024A1 (en) * | 1993-06-01 | 1994-12-08 | Enzon, Inc. | Carbohydrate-modified polymer conjugates with erythropoietic activity |
| US5621039A (en) | 1993-06-08 | 1997-04-15 | Hallahan; Terrence W. | Factor IX- polymeric conjugates |
| WO1996040662A2 (en) | 1995-06-07 | 1996-12-19 | Cellpro, Incorporated | Aminooxy-containing linker compounds and their application in conjugates |
| WO1999003496A1 (en) | 1997-07-21 | 1999-01-28 | The University Of North Carolina At Chapel Hill | Factor ix antihemophilic factor with increased clotting activity |
| US7074878B1 (en) | 1999-12-10 | 2006-07-11 | Harris J Milton | Hydrolytically degradable polymers and hydrogels made therefrom |
| US6413507B1 (en) | 1999-12-23 | 2002-07-02 | Shearwater Corporation | Hydrolytically degradable carbamate derivatives of poly (ethylene glycol) |
| AU2001258536A1 (en) | 2000-05-16 | 2001-11-26 | Lipoxen Technologies Limited | Derivatisation of proteins in aqueous solution |
| US7265084B2 (en) | 2001-10-10 | 2007-09-04 | Neose Technologies, Inc. | Glycopegylation methods and proteins/peptides produced by the methods |
| EP1446438A2 (en) | 2001-11-07 | 2004-08-18 | Nektar Therapeutics Al, Corporation | Branched polymers and their conjugates |
| MXPA05002594A (es) | 2002-09-11 | 2005-05-27 | Fresenius Kabi Gmbh | Derivados de polipeptidos con hidroxialquilalmidon, especialmente derivados de eritropoyetina con hidroxialquilalmidon. |
| WO2004089280A2 (en) | 2003-04-08 | 2004-10-21 | Yeda Research And Development Co. Ltd. | Reversible pegylated drugs |
| CA2522345A1 (en) | 2003-04-09 | 2004-11-18 | Neose Technologies, Inc. | Glycopegylation methods and proteins/peptides produced by the methods |
| WO2005014024A2 (en) * | 2003-08-08 | 2005-02-17 | Fresenius Kabi Deutschland Gmbh | Conjugates of a polymer and a protein linked by an oxime linking group |
| EP1654290B1 (en) | 2003-08-12 | 2019-03-13 | Lipoxen Technologies Limited | Sialic acid derivatives for protein derivatisation and conjugation |
| US8633157B2 (en) | 2003-11-24 | 2014-01-21 | Novo Nordisk A/S | Glycopegylated erythropoietin |
| ES2422187T3 (es) | 2003-12-03 | 2013-09-09 | Biogenerix Ag | Factor estimulante de colonias de granulocitos glicopegilados |
| US20060040856A1 (en) | 2003-12-03 | 2006-02-23 | Neose Technologies, Inc. | Glycopegylated factor IX |
| EP1776389B1 (en) | 2004-08-12 | 2016-06-29 | Lipoxen Technologies Limited | Sialic acid derivatives |
| WO2006031811A2 (en) | 2004-09-10 | 2006-03-23 | Neose Technologies, Inc. | Glycopegylated interferon alpha |
| AU2005322067B8 (en) | 2004-12-27 | 2012-07-26 | Takeda Pharmaceutical Company Limited | Polymer-von Willebrand factor-conjugates |
| CA2611823C (en) | 2005-06-16 | 2013-07-30 | Nektar Therapeutics Al, Corporation | Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates |
| US7645860B2 (en) | 2006-03-31 | 2010-01-12 | Baxter Healthcare S.A. | Factor VIII polymer conjugates |
| US20100056428A1 (en) | 2006-09-01 | 2010-03-04 | Novo Nordisk Health Care Ag | Modified proteins |
| DK2101821T3 (da) | 2006-12-15 | 2014-10-06 | Baxter Healthcare Sa | Faktor VIIA-(poly)sialinsyre-konjugat med forlænget halveringstid in vivo |
| GB0908393D0 (en) * | 2009-05-15 | 2009-06-24 | Almac Sciences Scotland Ltd | Labelling method |
| BR112012001814A8 (pt) * | 2009-07-27 | 2018-02-06 | Baxalta GmbH | Conjugados de proteína de coagulação sanguínea |
| EP3081233B1 (en) * | 2009-07-27 | 2020-12-23 | Baxalta GmbH | Glycopolysialylation of proteins other than blood coagulation proteins |
| TWI534152B (zh) * | 2010-07-30 | 2016-05-21 | 巴克斯特國際公司 | 用於肟連接的親核性催化劑 |
| KR101560541B1 (ko) * | 2012-04-13 | 2015-10-19 | 아우토리브 디벨롭먼트 아베 | 에어백 모듈과 스티어링 휠의 조립체 |
| AU2013204754C1 (en) * | 2012-05-16 | 2018-10-11 | Takeda Pharmaceutical Company Limited | Nucleophilic Catalysts for Oxime Linkage |
-
2013
- 2013-04-12 AU AU2013204754A patent/AU2013204754C1/en active Active
- 2013-05-16 SG SG10201911328QA patent/SG10201911328QA/en unknown
- 2013-05-16 KR KR1020217009701A patent/KR102287040B1/ko active Active
- 2013-05-16 BR BR112014028636-1A patent/BR112014028636B1/pt active IP Right Grant
- 2013-05-16 SG SG11201407597XA patent/SG11201407597XA/en unknown
- 2013-05-16 EA EA201790935A patent/EA035506B1/ru not_active IP Right Cessation
- 2013-05-16 CN CN201811295900.8A patent/CN109620963B/zh active Active
- 2013-05-16 EP EP21214357.2A patent/EP4019049A1/en active Pending
- 2013-05-16 NZ NZ738844A patent/NZ738844A/en unknown
- 2013-05-16 MX MX2014013919A patent/MX360594B/es active IP Right Grant
- 2013-05-16 WO PCT/US2013/041300 patent/WO2013173557A1/en not_active Ceased
- 2013-05-16 NZ NZ701945A patent/NZ701945A/en unknown
- 2013-05-16 EP EP13724491.9A patent/EP2849794A1/en not_active Withdrawn
- 2013-05-16 KR KR1020217024432A patent/KR102326360B1/ko active Active
- 2013-05-16 KR KR1020147035113A patent/KR102110622B1/ko active Active
- 2013-05-16 NZ NZ724828A patent/NZ724828A/en unknown
- 2013-05-16 CA CA2873756A patent/CA2873756C/en active Active
- 2013-05-16 CN CN201380037823.5A patent/CN104487095B/zh active Active
- 2013-05-16 JP JP2015512831A patent/JP6195611B2/ja active Active
- 2013-05-16 SG SG10201701780RA patent/SG10201701780RA/en unknown
- 2013-05-16 EA EA201492115A patent/EA028186B9/ru not_active IP Right Cessation
- 2013-05-16 KR KR1020207013096A patent/KR102237306B1/ko active Active
- 2013-05-16 NZ NZ738846A patent/NZ738846A/en unknown
- 2013-05-16 EP EP13728026.9A patent/EP2849795B1/en active Active
- 2013-05-16 WO PCT/US2013/041280 patent/WO2013173543A1/en not_active Ceased
-
2017
- 2017-06-01 JP JP2017109323A patent/JP6560712B2/ja active Active
-
2019
- 2019-02-05 JP JP2019018663A patent/JP6711935B2/ja active Active
-
2020
- 2020-04-03 JP JP2020067396A patent/JP7014844B2/ja active Active
-
2021
- 2021-12-29 JP JP2021215385A patent/JP7304402B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ738846A (en) | Nucleophilic catalysts for oxime linkage | |
| Stern et al. | The hyaluronidases: their genomics, structures, and mechanisms of action | |
| Mero et al. | Hyaluronic acid bioconjugates for the delivery of bioactive molecules | |
| CN103613686B (zh) | 巯基化透明质酸的制备方法及其应用 | |
| Masuko et al. | Thiolation of chitosan. Attachment of proteins via thioether formation | |
| Bo et al. | Sulfation and biological activities of konjac glucomannan | |
| JP5812537B2 (ja) | アミノ糖含有グルカン、その製造法および利用 | |
| WO2002018448A3 (en) | Percarboxylated polysaccharides, and a process for their preparation | |
| Wilson et al. | 1H NMR spectroscopic studies establish that heparanase is a retaining glycosidase | |
| DeAngelis | Heparosan, a promising ‘naturally good’polymeric conjugating vehicle for delivery of injectable therapeutics | |
| Wang et al. | Characterization and comparison of carboxymethylation and TEMPO-mediated oxidation for polysaccharides modification | |
| Silva et al. | Polysaccharides from exudate gums of plants and interactions with the intestinal microbiota: A review of vegetal biopolymers and prediction of their prebiotic potential | |
| Singh et al. | Bioactive and drug-delivery potentials of polysaccharides and their derivatives | |
| CN106866998A (zh) | 一种壳聚糖季铵盐/羧甲基纤维素超吸水凝胶及其制备方法和应用 | |
| Baskaran et al. | Glycosaminoglycan-mimetic biomaterials. 3. Glycopolymers prepared from alkene-derivatized mono-and disaccharide-based glycomonomers | |
| Sousa et al. | Marine-origin polysaccharides and their chemically modified derivatives as sources of advanced biofunctional materials for biomedical applications | |
| KR101170033B1 (ko) | 알돈산 에스테르, 알돈산 에스테르를 포함하는 고형물과 용액, 알돈산 에스테르를 제조하는 방법, 약제 활성 성분 및 약제 활성 성분 제조 방법 | |
| WO2021098098A1 (zh) | 巯基改性透明质酸及其制备方法和用途 | |
| WO2008013735A8 (en) | Methods for conjugation of oligosaccharides or polysaccharides to protein carriers through oxime linkages via 3-deoxy-d-manno-octulsonic acid | |
| EP2636749B1 (en) | Non-reducing end-modified glucan, method for producing same, and use thereof | |
| CN105294870B (zh) | 一种螺旋藻多糖及其制备方法 | |
| CN100390203C (zh) | 在外科或治疗性治疗哺乳动物的方法中或在诊断方法中使用的高支化支链淀粉 | |
| Ming-Jiang et al. | Structural analysis of water-soluble polysaccharide PIP1 extracted from the cultured mycelium of Phellinus igniarius | |
| Engbert et al. | Identification of specific structural motifs in biopolymers that effectively accelerate calcium alumina cement | |
| CN109758607A (zh) | 抵抗透明质酸酶水解的交联透明质酸凝胶 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 MAY 2020 BY ANAQUA SERVICES Effective date: 20190418 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 MAY 2021 BY ANAQUA SERVICES Effective date: 20200424 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 MAY 2022 BY ANAQUA SERVICES Effective date: 20210421 |
|
| ASS | Change of ownership |
Owner name: TAKEDA PHARMACEUTICAL COMPANY, JP Effective date: 20210621 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 MAY 2023 BY ANAQUA SERVICES Effective date: 20220423 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 MAY 2024 BY ANAQUA SERVICES Effective date: 20230420 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 MAY 2025 BY ANAQUA SERVICES Effective date: 20240418 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 MAY 2026 BY ANAQUA SERVICES Effective date: 20250423 |